Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7% - Should You Sell?

Key Points

• Kailera Therapeutics shares fell 7% to about $15.28, with trading volume 69% below the average session volume. The company has a market capitalization of approximately $1.97 billion.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $42.75; individual targets include $30 from JPMorgan and $48 from Jefferies.
• The company reported a quarterly loss of $1.09 per share, missing the $0.74 consensus estimate, while several institutional investors—including Wellington Management and Frazier Life Sciences—recently established positions.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report)'s share price fell 7% during trading on Wednesday . The company traded as low as $15.27 and last traded at $15.28. 222,361 shares changed hands during mid-day trading, a decline of 69% from the average session volume of 726,007 shares. The stock had previously closed at $16.43.

Analysts Set New Price Targets

KLRA has been the topic of several research analyst reports. JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an "overweight" rating and a $30.00 price target on the stock. Evercore began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an "outperform" rating on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a "hold" rating in a research report on Wednesday, May 13th. Jefferies Financial Group began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a "buy" rating and a $48.00 price target on the stock. Finally, William Blair started coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an "outperform" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Stock Down 7.4%

The company's 50 day moving average is $18.32. The company has a market cap of $1.97 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.35). Sell-side analysts expect that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KLRA. California State Teachers Retirement System bought a new position in Kailera Therapeutics in the 2nd quarter worth $309,000. Tidal Investments LLC bought a new stake in Kailera Therapeutics during the second quarter valued at about $309,000. Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics in the second quarter valued at about $993,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics in the second quarter valued at about $24,233,000. Finally, Wellington Management Group LLP bought a new position in shares of Kailera Therapeutics in the second quarter worth about $64,308,000.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.